- Home
- REGN vs HON Comparison
REGN vs HON Comparison
Compare REGN & HON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | REGN | HON |
|---|---|---|
| Founded | 1988 | 1885 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Aerospace |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.8B | 68.4B |
| IPO Year | 1995 | 2012 |
Fundamental Metrics
Financial Performance| Metric | REGN | HON |
|---|---|---|
| Price | $833.56 | $215.60 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 25 | 13 |
| Target Price | ★ $830.16 | $249.92 |
| AVG Volume (30 Days) | 713.4K | ★ 2.8M |
| Earning Date | 04-29-2026 | 04-23-2026 |
| Dividend Yield | 0.55% | ★ 2.26% |
| EPS Growth | ★ 8.19 | N/A |
| EPS | 18.95 | ★ 20.39 |
| Revenue | $5,872,227,000.00 | ★ $36,529,000,000.00 |
| Revenue This Year | $12.45 | $6.74 |
| Revenue Next Year | $10.13 | $5.91 |
| P/E Ratio | $43.72 | ★ $10.53 |
| Revenue Growth | ★ 20.82 | 12.92 |
| 52 Week Low | $541.00 | $186.76 |
| 52 Week High | $847.00 | $252.00 |
Technical Indicators
Market Signals| Indicator | REGN | HON |
|---|---|---|
| Relative Strength Index (RSI) | 73.46 | 32.30 |
| Support Level | $732.04 | $208.28 |
| Resistance Level | N/A | $221.04 |
| Average True Range (ATR) | 18.28 | 5.48 |
| MACD | -0.15 | -3.20 |
| Stochastic Oscillator | 78.15 | 3.90 |
Price Performance
Historical ComparisonAbout REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
About HON Honeywell International Inc.
Honeywell traces its roots to 1885 with Albert Butz's firm, Butz Thermo-Electric Regulator, which produced a predecessor to the modern thermostat. Other inventions by Honeywell include biodegradable detergent and autopilot. Today, Honeywell is a global multi-industry behemoth with one of the largest installed bases of equipment. It operates through four business segments: aerospace technologies, industrial automation, energy and sustainability solutions, and building automation. Recently, Honeywell has made several portfolio changes to focus on fewer end markets and align with a set of secular growth trends. The firm is working diligently to expand its installed base, deriving around one third of its revenue from recurring aftermarket services.